2CUREX AB SEK-10
2cureX AB (publ) operates as a medical technology company in Europe. The company's principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient's tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.
2CUREX AB SEK-10 (2QE) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, 2CUREX AB SEK-10 (2QE) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
2CUREX AB SEK-10 - Net Assets Trend (None–None)
This chart illustrates how 2CUREX AB SEK-10's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 2CUREX AB SEK-10 (None–None)
The table below shows the annual net assets of 2CUREX AB SEK-10 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to 2CUREX AB SEK-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
2CUREX AB SEK-10 Competitors by Market Cap
The table below lists competitors of 2CUREX AB SEK-10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TTGXF
OTCQB:TTGXF
|
$1.39 Million |
|
CLASS 1 NICKEL+TECH.LTD
F:77C
|
$1.39 Million |
|
GOLDON RES LTD
F:6NR2
|
$1.39 Million |
|
Medallion Resources Ltd
PINK:MLLOF
|
$1.39 Million |
|
Fitters Diversified Bhd
KLSE:9318
|
$1.39 Million |
|
Rav Bariach 08 Industries Ltd
TA:BRIH
|
$1.39 Million |
|
Centaurus Energy Inc
PINK:CTARF
|
$1.39 Million |
|
Avada Group Ltd
AU:AVD
|
$1.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 2CUREX AB SEK-10's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares 2CUREX AB SEK-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently 2CUREX AB SEK-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares 2CUREX AB SEK-10's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 2CUREX AB SEK-10 (2QE) | €- | N/A | N/A | $1.39 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |